Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
First protease inhibitor combination pill maintains viral suppression

The first once-daily single-tablet regimen containing a protease inhibitor maintained viral suppression in almost everyone who switched after achieving undetectable HIV RNA on a multi-pill

Published
01 August 2017
By
Liz Highleyman
New HIV capsid inhibitors show high potency and prolonged activity in early studies

A novel type of antiretroviral drug that interferes with the assembly and disassembly of the HIV capsid, which encloses the genetic blueprint of the virus, may offer

Published
03 March 2017
By
Liz Highleyman
People With Multidrug-Resistant HIV Can Now Start Treatment on the Experimental Drug Ibalizumab

Ibalizumab is a new drug that is effective against drug resistant HIV. It is not approved for sale in the United States, but patients can take advantage of an expanded access program to start treatment right away.

Published
15 December 2016
From
TheBody.com
Ibalizumab monoclonal antibody looks promising for people with drug-resistant HIV

Ibalizumab, an experimental monoclonal antibody with a unique mechanism of action, demonstrated good safety and promising efficacy in a small phase 3 study of people with extensive

Published
04 November 2016
By
Liz Highleyman
HIV salvage regimens can safely omit NRTIs, says US study

Nucleoside reverse transcriptase inhibitors (NRTIs) can be safely omitted from HIV salvage therapy, investigators from the United States report in the Annals of Internal Medicine. The findings

Published
04 January 2016
By
Michael Carter
HIV attachment inhibitor BMS-663068 matches atazanavir in phase 2b study

Bristol-Myers Squibb’s HIV attachment inhibitor BMS-663068 (fostemsavir), which prevents the virus from binding to T-cells, demonstrated good antiviral activity and was well-tolerated at 24 weeks, according to study

Published
14 October 2015
By
Liz Highleyman
Raltegravir appears to prevent mother-to-child HIV transmission during late pregnancy

Combination antiretroviral therapy containing the integrase inhibitor raltegravir (Isentress) appears safe and effective and may be an attractive option for treatment for pregnant women with HIV –

Published
28 July 2015
By
Liz Highleyman
Exploring possible treatment options after virological failure with raltegravir

In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.

Published
21 January 2015
From
CATIE
British HIV cure survey: most respondents would be prepared to take some health risk to help find a cure for HIV

An online survey that asked people living with HIV, largely from the UK, whether they would participate in HIV cure research, has found that the majority of

Published
28 November 2014
By
Gus Cairns
Higher pill burden is associated with poorer adherence to HIV therapy and reduced chances of achieving an undetectable viral load

Lower pill burden is associated with higher rates of adherence to HIV treatment and better virological outcomes, according to the results of a meta-analysis published in the online

Published
31 January 2014
By
Michael Carter
← First12345...15Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.